Patent ID: 11919881
Assignee: JANSSEN PHARMACEUTICA NV
Field: Organic fine chemistry (Chemistry)
Classification: CPC C | IPC C

Claim 0:
1. A compound of formula (I-M), wherein
R1 is selected from the group consisting of halogen, hydroxy, C1-4alkyl, fluorinated C1-4alkyl, C1-4alkoxy, fluorinated C1-4alkoxy, cyano, nitro, —NRARB, —C(O)—C1-4alkyl, C3-6cycloalkyl, phenyl and 5 to 6 membered heterocyclyl;
wherein the C3-6cycloalkyl, phenyl or 5 to 6 membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, cyano, C1-4alkyl, fluorinated C1-4alkyl, C1-4alkoxy, fluorinated C1-4alkoxy, —C(O)OH and —C(O)O—(C1-4alkyl);
and wherein RA and RB are each independently selected from the group consisting of hydrogen and C1-4alkyl;
a is an integer from 0 to 3;
each R2 is independently selected from the group consisting of chloro, fluoro, methyl and methoxy;
R4 is selected from the group consisting of
(a) phenyl; wherein the phenyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated C1-2alkoxy, —C(O)OH, —C(O)—O—(C1-4alkyl), —NRCRD, —(C1-2alkylene)-NRCRD, and —C(O)—NRCRD;
wherein RC is selected from the group consisting of hydrogen, C1-4alkyl, cyclopropyl, 3-hydroxy-cycloprop-1-yl, —C(O)—C1-4alkyl, —C(O)-cyclopropyl, —C(O)—O—C1-4alkyl; and RD is selected from the group consisting of hydrogen and C1-4alkyl;
and (b) 5 to 6 membered heterocyclyl; wherein the 5 membered heterocyclyl contains at least one heteroatom selected from the group consisting of O, N and S; optionally contains 1 to 3 additional heteroatoms independently selected from the group consisting of O, N and S;
and wherein the 5 membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-4alkyl, fluorinated C1-4alkyl, C1-4alkoxy, fluorinated C1-4alkoxy, —C(O)OH, —C(O)—O—C1-4alkyl, —NRERF, and —C(O)—NRERF; wherein RE is selected from the group consisting of hydrogen, C1-4alkyl, cyclopropyl, 3-hydroxy-cycloprop-1-yl, —C(O)—C1-4alkyl, —C(O)-cyclopropyl and —C(O)—O—C1-4alkyl; and RF is selected from the group consisting of hydrogen and C1-4alkyl;
R5 is selected from the group consisting of (a) C1-4alkyl; wherein the C1-4alkyl is optionally substituted with one or more halogen, and further optionally substituted with a substituent selected from the group consisting of hydroxy, C1-4alkoxy, fluorinated C1-4alkoxy, —C(O)OH, and —C(O)—O—(C1-4alkyl);
(b) —CH2—C3-8cycloalkyl; wherein the C3-8cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C1-4alkyl;
(c) -L1 (5 to 6 membered saturated heterocyclyl); wherein L1 is —CH2—; and wherein the 5 to 6 membered saturated heterocyclyl is optionally substituted with one to two oxo groups;
and (d) —C1-2alkylene-phenyl; wherein the phenyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-4alkyl, fluorinated C1-4alkyl, C1-4alkoxy, and fluorinated C1-4alkoxy;
R6 and R7 are each independently selected from the group consisting of hydrogen, halogen, C1-4alkyl and C1-4alkoxy; provided that at least one of R6 or R7 is hydrogen;
or a stereoisomer, isotopologue, isotopomer, or pharmaceutically acceptable salt or solvate thereof.